Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)

Corral, Julieta; Espinàs, Josep Alfons; Cots, Francesc; Pareja, Laura; Solà, Judit; Font, Rebeca; Borràs, Josep Maria

doi:10.1186/s12913-015-0725-3

BMC Health Services Research

Table 4 Mean hospital costs of lung cancer diagnosis and treatment per patient by sex, age group, stage at diagnosis, survival at one year from diagnosis and cost type (Euros, 2008)

From: Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)

	Diagnosis		Surgery		Chemotherapy		Radiotherapy		Other inpatient care		Continuing care		Total mean cost		p-value
NSCLC (mean, [sd], %)
Male	2,998	[3,264]	3,272	[4,838]	3,261	[8,354]	432	[785]	2,982	[4,805]	678	[910]	13,624	[10,649]	0.072
(N = 146)	22.0%		24.0%		23.9%		3.2%		21.9%		5.0%		100.0%
Female	3,277	[3,089]	3,955	[5,542]	10,654	[19,139]	242	[595]	2,777	[4,738]	616	[979]	21,521	[19,367]
(N = 26)	15.2%		18.4%		49.5%		1.1%		12.9%		2.9%		100%
<65 years	2,880	[3,058]	3,436	[5,338]	4,890	[10,060]	403	[740]	2,981	[5,078]	679	[906]	15,270	[12,600]	0.716
(N = 76)	18.9%		22.5%		32.0%		2.6%		19.5%		4.4%		100.0%
≥65 years	3,167	[3,372]	3,327	[4,628]	3,973	[11,634]	403	[781]	2,928	[4,561]	661	[932]	14,460	[12,674]
(N = 96)	21.9%		23.0%		27.5%		2.8%		20.2%		4.6%		100.0%
Stage I	733	[551]	7,849	[4,515]	699	[2,179]	327	[745]	2,632	[5,285]	1,081	[864]	13,321	[8,316]	0.289
(N = 39)	5.5%		58.9%		5.2%		2.5%		19.8%		8.1%		100.0%
Stage II	1,464	[1,131]	7,401	[4,898]	2,511	[4,887]	594	[811]	2,935	[4,142]	1,213	[1,333]	16,120	[7,632]
(N = 11)	9.1%		45.9%		15.6%		3.7%		18.2%		7.5%		100.0%
Stage III	3,318	[2,576]	1,989	[4,159]	2,749	[6,452]	721	[978]	3,581	[5,051]	860	[1,235]	13,218	[10,240]
(N = 36)	25.1%		15.0%		20.8%		5.5%		27.1%		6.5%		100.0%
Stage IV	4,042	[3,299]	322	[1,610]	6,876	[13,283]	327	[661]	3,210	[4,853]	263	[416]	15,044	[14,338]
(N = 71)	26.9%		2.1%		45.7%		2.2%		21.3%		1.7%		100.0%
Unknown	4,786	[5,423]	6,574	[6,133]	7,402	[18,928]	60	[232]	1,055	[2,059]	645	[833]	20,522	[19,336]
(N = 15)	23.3%		32.0%		36.1%		0.3%		5.1%		3.1%		100.0%
Alive 1 year	2,644	[3,138]	4,814	[5,372]	4,427	[10,847]	472	[812]	2,661	[4,477]	938	[1,038]	15,955	[12,202]	0.002
(N = 106)	16.6%		30.2%		27.7%		3.0%		16.7%		5.9%		100.0%
Dead 1 year	3,677	[3,300]	1,066	[2,961]	4,301	[11,183]	293	[661]	3,418	[5,237]	237	[409]	12,991	[13,129]
(N = 66)	28.3%		8.2%		33.1%		2.3%		26.3%		1.8%		100.0%
Total	3,040	[3,231]	3,376	[4,939]	4,378	[10,945]	403	[761]	2,951	[4,782]	669	[918]	14,818	[12,611]
(N = 172)	20.5%		22.8%		29.5%		2.7%		19.9%		4.5%		100.0%
SCLC (mean, [sd], %)
Male	2,708	[2,350]	-		4,646	[10,164]	878	[952]	2,747	[3,627]	694	[791]	11,674	[11,089]	0.078
(N = 23)	23.2%				39.8%		7.5%		23.5%		5.9%		100.0%
Female	3,041	[1,905]	-		3,412	[2,889]	814	[912]	9,915	[8,846]	1,345	[1,272]	18,527	[9,054]
(N = 3)	16.4%				18.4%		4.4%		53.5%		7.3%		100.0%
<65 years	2,159	[1,993]	-		7,361	[13,510]	1,114	[981]	5,580	[6,000]	1,080	[930]	17,294	[14,093]	0.006
(N = 12)	12.5%				42.6%		6.4%		32.3%		6.2%		100.0%
≥65 years	3,251	[2,443]	-		2,055	[2,824]	661	[864]	1,855	[2,726]	503	[706]	8,325	[4,718]
(N = 14)	39.1%				24.7%		7.9%		22.3%		6.0%		100.0%
Limited disease	1,689	[1,757]	-		4,851	[3,380]	1,671	[1,187]	6,133	[7,057]	1,074	[867]	15,418	[10,105]	0.140
(N = 7)	11.0%				31.5%		10.8%		39.8%		7.0%		100.0%
Extensive disease	2,813	[2,175]	-		5,192	[11,989]	683	[624]	3,046	[3,672]	748	[888]	12,482	[12,007]
(N = 16)	22.5%				41.6%		5.5%		24.4%		6.0%		100.0%
Unknown	4,861	[3,018]	-		22	[39]	-		422	[731]	175	[208]	5,481	[2,378]
(N = 3)	88.7%				0.4%				7.7%		3.2%		100.0%
Alive 1 year	2,388	[2,047]	-		2,976	[2,784]	1,436	[1,093]	1,431	[2,652]	1,086	[1,008]	9,316	[3,443]	0.597
(N = 9)	25.6%				31.9%		15.4%		15.4%		11.7%		100.0%
Dead 1 year	2,937	[2,420]	-		5,313	[11,724]	571	[692]	4,709	[5,378]	602	[735]	14,131	[13,140]
(N = 17)	20.8%				37.6%		4.0%		33.3%		4.3%		100.0%
Total	2,747	[2,272]	-		4,504	[9,578]	870	[930]	3,574	[4,826]	769	[852]	12,465	[10,943]
(N = 26)	22.0%				36.1%		7.0%		28.7%		6.2%		100.0%
NCC (mean, [sd], %)
Male	3,901	[3,538]	1,100	[3,063]	183	[533]	36	[136]	4,768	[16,839]	129	[254]	10,116	[18,410]	0.645
(N = 25)	38.6%		10.9%		1.8%		0.4%		47.1%		1.3%		100.0%
Female	3,802	[2,945]	871	[2,612]	9,586	[17,920]	427	[1,282]	2,597	[4,336]	447	[604]	17,729	[23,745]
(N = 9)	21.4%		4.9%		54.1%		2.4%		14.6%		2.5%		100.0%
<65 years	2,961	[3,609]	3,085	[4,261]	10,040	[19,035]	513	[1,350]	14,563	[28,241]	293	[476]	31,455	[34,191]	0.009
(N = 8)	9.4%		9.8%		31.9%		1.6%		46.3%		0.9%		100.0%
≥65 years	4,156	[3,286]	410	[2,091]	405	[1,504]	25	[126]	1,002	[3,338]	189	[373]	6,186	[6,128]
(N = 26)	67.2%		6.6%		6.5%		0.4%		16.2%		3.1%		100.0%
Stage I	1,098	[998]	8,422	[0]	-		-		41,714	[58,992]	350	[496]	51,584	[59,495]	0.231
(N = 2)	2.1%		16.3%						80.9%		0.7%		100.0%
Stage II	-		-		-		-		-		-		-
(N = 0)
Stage III	2,031	[2,498]	-		1,850	[3,700]	-		1,469	[1,300]	470	[550]	5,819	[6,680]
(N = 4)	34.9%				31.8%				25.2%		8.1%		100.0%
Stage IV	3,659	[2,869]	490	[1,959]	5,069	[13,981]	297	[962]	2,029	[4,090]	186	[436]	11,729	[18,728]
(N = 16)	31.2%		4.2%		43.2%		2.5%		17.3%		1.6%		100.0%
Unknown	5,239	[3,984]	888	[3,077]	195	[674]	-		1,733	[4,840]	142	[261]	8,197	[7,585]
(N = 12)	64.1%		10.8%		2.4%				21.1%		1.7%		100.0%
Alive 1 year	3,493	[2,978]	1,860	[3,735]	2,088	[6,677]	216	[881]	5,861	[19,080]	333	[478]	13,851	[22,728]	0.242
(N = 19)	25.2%		13.4%		15.1%		1.6%		42.3%		2.4%		100.0%
Dead 1 year	4,358	[3,816]	-		3,411	[12,939]	43	[166]	2,080	[4,734]	62	[171]	9,954	[16,042]
(N = 15)	43.8%				34.3%		0.4%		20.9%		0.6%		100.0%
Total	3,875	[3,348]	1,039	[2,914]	2,672	[9,787]	140	[666]	4,193	[14,550]	213	[394]	12,132	[19,869]
(N = 34)	31.9%		8.6%		22.0%		1.2%		34.6%		1.8%		100.0%

NSCLC: non-small cell lung cancer.
SCLC: small cell lung cancer.
NCC: no cytohistologic confirmation.
sd: standard deviation.

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com